

FORM 1449\*

## INFORMATION DISCLOSURE STATEMENT

Docket Number:

11757.0104USWO

Application Number:

10/510,321

IN AN APPLICATION

(Use several sheets if necessary)

Applicant: DIAMANDIS et al.

Filing Date: May 25, 2005

Group Art Unit: 1645



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/AMG/	JP 10-133615	11/1999	Japan			Abstract	
/AMG/	JP 8-056367	11/1996	Japan			Abstract	
/AMG/	WO 99/09138	02/1999	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/AMG/	Chen et al., "Expression and Activity-Dependent Changes of a Novel Limbic-Serine Protease Gene in the Hippocampus", The Journal of Neuroscience (1995); 15(7): 5088-5097
	Christensson et al., "Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors", European Journal of Biochemistry (1990); 194: 755-763
	Christopoulos et al., "Enzymatically Amplified Time-Resolved Fluorescence Immunoassay with Terbium Chelates", Analytical Chemistry (1992); 64(4): 342-346
	Diamandis et al., "Human Kallikrein 11: A New Biomarker of Prostate and Ovarian Carcinoma", Cancer Research (2002); 62: 295-300
	Diamandis et al., "Human tissue kallikrein gene family: a rich source of novel disease biomarkers", Expert Reviews in Molecular Diagnosis (2001); 1(2): 182-190
	Diamandis et al., "New Nomenclature for the Human Tissue Kallikrein Gene Family", Clinical Chemistry (2000); 46(11): 1855-1858
	Diamandis et al., "The New Human Kallikrein Gene Family: Implications in Carcinogenesis", TEM (2000); 11(2): 54-60
	Diamandis et al., "Human Kallikrein 6 (Zyme/Protease M/Neurosin): A New Serum Biomarker of Ovarian Carcinoma", Clinical Biochemistry (2000); 33(7): 579-583
	Ferguson et al., "Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers", Clinical Chemistry (1996); 42(5): 675-684
/AMG/	Hassapoglidou et al., "Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry", Oncogene (1993); 8: 1501-1509

EXAMINER

/Anne M. Gussow/

DATE CONSIDERED

04/24/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 11757.0104USWO	Application Number: 10/510,321
	Applicant: DIAMANDIS et al.	
	Filing Date: May 25, 2005	Group Art Unit: 1645

/AMG/	Kishi et al., "Crystal Structure of Neuropin, a Hippocampal Protease Involved in Kindling Epileptogenesis", The Journal of Biological Chemistry (1999); 274(7): 4220-4224
	Kornai et al., "Neuropin regulates an early phase of Schaffer-collateral long-term potentiation in the murine hippocampus", European Journal of Neuroscience (2000); 12: 1479-1486
	Luo et al., "Human Kallikrein 10: a novel tumor marker for ovarian carcinoma?", Clinica Chimica Acta (2001); 306: 111-118
	Luo et al., "Immunofluorometric Assay of Human Kallikrein 10 and Its Identification in Biological Fluids and Tissues", Clinical Chemistry (2001); 47(2): 237-246
	Magklara et al., "The Human KLK8 (Neuropin/Ovasin) Gene: Identification of Two Novel Splice Variants and its Prognostic Value in Ovarian Cancer", Clinical Cancer Research (2001); 7: 806-811
	Mitsui et al., "A novel form of human neuropin, a brain-related serine protease, is generated by alternative splicing and is expressed preferentially in human adult brain", European Journal of Biochemistry (1999); 260: 627-634
	Momota et al., "Blockade of neuropin, a serine protease, ameliorates kindling epilepsy", European Journal of Neuroscience (1998); 10: 760-764
	Petraki et al., "The Spectrum of Human Kallikrein 6 (Zyme/Protease M/Neuropin Expression in Human Tissues as Assessed by Immunohistochemistry", The Journal of Histochemistry and Cytochemistry (2001); 48(11): 1431-1441
	Shimizu et al., "Characterization of Recombinant and Brain Neuropin, a Plasticity-related Serine Protease", The Journal of Biological Chemistry (1998); 273(18): 11189-11196
	Shimizu-Okabe et al., "Expression of the kallikrein gene family in normal and Alzheimer's disease brain", Molecular Neuroscience (2001); 12(12): 2747-2751
	Stamey et al., "Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate", The New England Journal of Medicine (1987); 317(15): 909-914
	Stenman et al., "A Complex between Prostate-specific Antigen and $\alpha_1$ -Antichymotrypsin Is the Major Form of Prostate-specific Antigen in Serum of Patients with Prostatic Cancer: Assay of the Complex Improves Clinical Sensitivity for Cancer", Cancer Research (1991); 51: 222-226
	Stephan et al., "Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer", Cancer Epidemiology, Biomarkers & Prevention (2000); 9: 1133-1147
	Underwood et al., "Cloning of Tumor-associated Differentially Expressed Gene-14, a Novel Serine Protease Overexpressed by Ovarian Cancer", Cancer Research (1999); 59: 4435-4439
	Yoshida et al., "Sequence analysis and expression of human neuropin cDNA and gene", Gene (1998); 213: 9-16
	Yousef et al., "The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease", Endocrine Reviews (2001); 22(2): 184-204
/AMG/	Yousef et al., "The New Kallikrein-like Gene, KLK-L2", The Journal of Biological Chemistry (1999); 274(53): 37511-37516

EXAMINER /Anne M. Gussow/	DATE CONSIDERED 04/24/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	<b>Docket Number:</b> 11757.0104USWO	<b>Application Number:</b> 10/510,321
	<b>Applicant:</b> DIAMANDIS et al.	
	<b>Filing Date:</b> May 25, 2005	<b>Group Art Unit:</b> 1645

/AMG/	Yu et al., "Ultrasensitive Time-Resolved Immunofluorometric Assay of Prostate-Specific Antigen in Serum and Preliminary Clinical Studies", Clinical Chemistry (1993); 39(10); 2108-2114
-------	---

<b>23552</b> PATENT TRADEMARK OFFICE
---

<b>EXAMINER</b> /Anne M. Gussow/	<b>DATE CONSIDERED</b> 04/24/2008
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	